Overview

Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Status:
Completed

Trial end date:
2017-10-09

Target enrollment:

Participant gender:

Summary

The primary objective was to assess the injection site pain associated with the new formulation of etanercept compared with commercial etanercept in adults with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) as measured by a visual analog scale (VAS).

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Etanercept